Key facts
- This page summarizes PATRICK DEVAL L's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Nov 2023, 16:15.
PATRICK DEVAL L - 01 Nov 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Nov 2023
- Net transaction value
- -$373,009
- SEC form
- 4
- Accepted by SEC
- 03 Nov 2023, 16:15:10 UTC
- Prior SEC filing
- 19 Sep 2023
- Next SEC filing
- 19 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Bodenrader, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
PATRICK DEVAL L filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 03 Nov 2023.
Change
- Previous filing in this sequence was filed on 19 Sep 2023.
- Current net transaction value: -$373,009.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CERE
transaction
Common Stock
Options Exercise
- Transaction value
- $380,241
- Shares
- +30,130
- Change %
- +918%
- Price
- $12.62
- Shares after
- 33,412
- Date
- 01 Nov 2023
- Ownership
- Direct
- Footnotes
- F1, F2
CERE
transaction
Common Stock
Sale
- Transaction value
- -$753,250
- Shares
- -30,130
- Change %
- -90%
- Price
- $25.00
- Shares after
- 3,282
- Date
- 01 Nov 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CERE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -30,130
- Change %
- -71%
- Price
- $0.000000
- Shares after
- 12,555
- Date
- 01 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,130
- Exercise price
- $12.62
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person.
Footnote F2
Includes 3,282 Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan that were previously reported by the Reporting Person.
Footnote F3
This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021.